Connect with us

International

Science Denied: The Biden Vaccine Mandate

Science Denied: The Biden Vaccine Mandate

Authored by Jeffrey Tucker via Brownstone.org,

President Biden has decided to go hard on the virus. No more Mr. Nice Guy.

Sadly for him, those tiny little pathogens don’t pay taxes, don’t vote,…

Published

on

Science Denied: The Biden Vaccine Mandate

Authored by Jeffrey Tucker via Brownstone.org,

President Biden has decided to go hard on the virus. No more Mr. Nice Guy.

Sadly for him, those tiny little pathogens don’t pay taxes, don’t vote, don’t have Social Security numbers, can’t be drafted, and don’t answer phone calls from poll takers, which is to say that he and his agencies cannot really control them. That must be frustrating, poor man. 

Instead his plan is to control what he can control: people, and, most immediately, federal workers and the employees of large regulated companies. For him, the key to crushing the virus is the vaccine. Not enough people are obeying his demand for near-universal vaccination. 

In a maniacal move of wild desperation – or as an excuse to try out the most extreme powers of his office – he is using every weapon that he believes he has to assure compliance with his dream of injecting as many arms as possible. Only then will we crush the virus, all thanks to his leadership, all the complaints about “freedom” be damned – and never mind that the realization of his dream did not work in Israel or the UK. 

What are the immediate problems here? At least five:

1. The Biden mandate pretends that the only immunity is injected, not natural. And so it has been from the beginning of this pandemic, even though all science for at least a year – actually you can say centuries – contradicts that. Indeed, we’ve known about natural immunity since 400 B.C when Thucydides first wrote of the great Athens plague that revealed that “they knew the course of the disease and were themselves free from apprehension.” Biden’s mandate could affect 80 million people but far more than that have likely been exposed and gained robust immunity regardless of vaccination status. 

2. This natural immunity is long-lasting and broad, and we’ve known that since last year when the first studies revealed it. You can say that the addition of a vaccine provides even more but it’s new and untested relative to most drugs approved by regulators, and many people are concerned about possible side effects of this vaccine that was approved much faster than any drug in my lifetime – and there is not one living human being in a position to say with certainty that these skeptics are wrong. 

3. The mandate presumes that everyone is equally susceptible to severe outcomes from getting exposed to the virus, which we’ve known is not true since at least February 2020. In this entire 18-month fiasco, we’ve not seen any serious high-level communication about the huge range of demographic gradients in infection based on both age and overall health. This ignorance is a consequence of poor public-health messaging, and is grossly irresponsible. The aggregated mandate from the Biden administration ignores this completely, as did the models that suggested lockdowns in the event of a virus from the Spring of 2020. 

4. Biden seems still of the belief that vaccines stop infection (he claimed this many times) and spread but we know with certainty that this is not the case, and even the CDC admits it. The best guess at this point is that it can help in preventing hospitalization and death but this experiment is still in its early stages, and the relationship between cause and effect in human affairs is not as easy as throwing around two data sets and saying one caused the other. Most cases in the developed world now are occurring among the vaccinated – and we all know this because we have vaccinated friends who got Covid anyway. Some have died. We are not idiots, contrary to what the Biden administration believes. Nor do any of us have all the knowledge and answers. And it is precisely because science is uncertain that the decisions surrounding it need to be decentralized, depoliticized, and open to correction rather than being imposed by top-down mandates. 

5. Biden’s order flies in the face of basic human freedoms and rights. There is no other way to put it. And it is this fact that is the most prescient for the multitudes who are right now seething in anger that one man who happens to hold power can make health decisions for the whole population regardless of their perfectly rational judgements. When the needle filled with liquid is forced into the arms of people who either have natural immunities or do not fear exposure to the pathogen, it gets personal, and people get really mad, especially after they are still forced into masks and denied other essential rights. 

Truth is that my phone has been blowing up all evening since Biden’s speech. People are demoralized, panicked, furious, and even at the point of losing it completely over this despotic moment in which we are living. Most of us believed that we live in a scientific age in which information would be broadly disseminated to the world and this technology would somehow prevent us as a society from falling prey to charlatans, mob mysticism, and brutal methods of population control, not to mention to the deployment of superstitious talismans and quackery. That turns out not to be true, and this is perhaps the greatest shock of all. 

Scientists worked for many hundreds of years to understand pathogens. They worked to understand their effect on the body, the range of susceptibility to both infection and severe outcomes, the demographics of vulnerability, the means by which we come to be protected from them, and the opportunities and limits available to people to protect themselves and others. After all this, humanity put together institutions that protected human freedom, individual rights, and public health, while preserving peace and prosperity in the best of times. 

In the last 18 months, all that hard work and knowledge seems to have been shredded, replaced by superstition masquerading as some kind of new science of social and pathogenic control. In this year and a half, we’ve observed no clear successes and unrelenting flops. One year ago, humanity had the opportunity to embrace the wisdom of the Great Barrington Declaration to protect the vulnerable while letting society otherwise function. Governments instead chose the path of ignorance and violence. The list is long but it includes: travel restrictions, capacity limits, business closures, school shutdowns, mask mandates, forced human separation (“social distancing”), and now mandates of vaccination that, quite apparently, vast numbers do not want. 

It’s all designed so that governments can prove to the world that they are powerful enough, smart enough, educated enough to outsmart and manage any living organism, even an invisible one that has been part of the human experience since humans had experiences. In this, they have completely failed – in more ways than it is possible to count. 

We keep thinking that surely, surely, we will come to the end of this madness. I personally believed it would end the second week of March 2020. Instead, it gets worse and worse, the illusion of control having seized the barely functioning brains of the ruling classes of the world’s richest nations. If this doesn’t prove the astonishing stupidity of the world’s most powerful and educated, nothing else in history does. 

The great myth that has clouded our vision and our expectations has been that we as a people had progressed beyond the kind of statist shibboleths and fanatic brutality that define our age. The truth is that we are not. 

This very day, a Karen attacked me for being maskless. I looked at her and thought only of the poor people in Colonial America who dared being caught wearing buckled shoes and therefore running afoul of the sumptuary laws, or of the religious minorities in Medieval Europe who were scapegoated for every plague (look up the origins of the the phrase “poisoning the well”), or the demonization of rebels in the ancient Roman empire or the disapprobation of heretics in the hundreds of years that followed the fall of Rome.

It is a mark of a primitive society to attribute to political compliance or noncompliance what rational science shows is a feature of the natural world. Why? Ignorance, maybe. Power ambitions, more likely. Scapegoating is apparently an eternal feature of the human experience. Governments seem particularly good at it, even when it is less believable than ever. 

Tyler Durden Tue, 09/14/2021 - 00:00

Read More

Continue Reading

International

Analyst reviews Apple stock price target amid challenges

Here’s what could happen to Apple shares next.

Published

on

They said it was bound to happen.

It was Jan. 11, 2024 when software giant Microsoft  (MSFT)  briefly passed Apple  (AAPL)  as the most valuable company in the world.

Microsoft's stock closed 0.5% higher, giving it a market valuation of $2.859 trillion. 

It rose as much as 2% during the session and the company was briefly worth $2.903 trillion. Apple closed 0.3% lower, giving the company a market capitalization of $2.886 trillion. 

"It was inevitable that Microsoft would overtake Apple since Microsoft is growing faster and has more to benefit from the generative AI revolution," D.A. Davidson analyst Gil Luria said at the time, according to Reuters.

The two tech titans have jostled for top spot over the years and Microsoft was ahead at last check, with a market cap of $3.085 trillion, compared with Apple's value of $2.684 trillion.

Analysts noted that Apple had been dealing with weakening demand, including for the iPhone, the company’s main source of revenue. 

Demand in China, a major market, has slumped as the country's economy makes a slow recovery from the pandemic and competition from Huawei.

Sales in China of Apple's iPhone fell by 24% in the first six weeks of 2024 compared with a year earlier, according to research firm Counterpoint, as the company contended with stiff competition from a resurgent Huawei "while getting squeezed in the middle on aggressive pricing from the likes of OPPO, vivo and Xiaomi," said senior Analyst Mengmeng Zhang.

“Although the iPhone 15 is a great device, it has no significant upgrades from the previous version, so consumers feel fine holding on to the older-generation iPhones for now," he said.

A man scrolling through Netflix on an Apple iPad Pro. Photo by Phil Barker/Future Publishing via Getty Images.

Future Publishing/Getty Images

Big plans for China

Counterpoint said that the first six weeks of 2023 saw abnormally high numbers with significant unit sales being deferred from December 2022 due to production issues.

Apple is planning to open its eighth store in Shanghai – and its 47th across China – on March 21.

Related: Tech News Now: OpenAI says Musk contract 'never existed', Xiaomi's EV, and more

The company also plans to expand its research centre in Shanghai to support all of its product lines and open a new lab in southern tech hub Shenzhen later this year, according to the South China Morning Post.

Meanwhile, over in Europe, Apple announced changes to comply with the European Union's Digital Markets Act (DMA), which went into effect last week, Reuters reported on March 12.

Beginning this spring, software developers operating in Europe will be able to distribute apps to EU customers directly from their own websites instead of through the App Store.

"To reflect the DMA’s changes, users in the EU can install apps from alternative app marketplaces in iOS 17.4 and later," Apple said on its website, referring to the software platform that runs iPhones and iPads. 

"Users will be able to download an alternative marketplace app from the marketplace developer’s website," the company said.

Apple has also said it will appeal a $2 billion EU antitrust fine for thwarting competition from Spotify  (SPOT)  and other music streaming rivals via restrictions on the App Store.

The company's shares have suffered amid all this upheaval, but some analysts still see good things in Apple's future.

Bank of America Securities confirmed its positive stance on Apple, maintaining a buy rating with a steady price target of $225, according to Investing.com

The firm's analysis highlighted Apple's pricing strategy evolution since the introduction of the first iPhone in 2007, with initial prices set at $499 for the 4GB model and $599 for the 8GB model.

BofA said that Apple has consistently launched new iPhone models, including the Pro/Pro Max versions, to target the premium market. 

Analyst says Apple selloff 'overdone'

Concurrently, prices for previous models are typically reduced by about $100 with each new release. 

This strategy, coupled with installment plans from Apple and carriers, has contributed to the iPhone's installed base reaching a record 1.2 billion in 2023, the firm said.

More Tech Stocks:

Apple has effectively shifted its sales mix toward higher-value units despite experiencing slower unit sales, BofA said.

This trend is expected to persist and could help mitigate potential unit sales weaknesses, particularly in China. 

BofA also noted Apple's dominance in the high-end market, maintaining a market share of over 90% in the $1,000 and above price band for the past three years.

The firm also cited the anticipation of a multi-year iPhone cycle propelled by next-generation AI technology, robust services growth, and the potential for margin expansion.

On Monday, Evercore ISI analysts said they believed that the sell-off in the iPhone maker’s shares may be “overdone.”

The firm said that investors' growing preference for AI-focused stocks like Nvidia  (NVDA)  has led to a reallocation of funds away from Apple. 

In addition, Evercore said concerns over weakening demand in China, where Apple may be losing market share in the smartphone segment, have affected investor sentiment.

And then ongoing regulatory issues continue to have an impact on investor confidence in the world's second-biggest company.

“We think the sell-off is rather overdone, while we suspect there is strong valuation support at current levels to down 10%, there are three distinct drivers that could unlock upside on the stock from here – a) Cap allocation, b) AI inferencing, and c) Risk-off/defensive shift," the firm said in a research note.

Related: Veteran fund manager picks favorite stocks for 2024

Read More

Continue Reading

International

Major typhoid fever surveillance study in sub-Saharan Africa indicates need for the introduction of typhoid conjugate vaccines in endemic countries

There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high…

Published

on

There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high burden combined with the threat of typhoid strains resistant to antibiotic treatment calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines (TCVs) in endemic settings along with improvements in access to safe water, sanitation, and hygiene.

Credit: IVI

There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high burden combined with the threat of typhoid strains resistant to antibiotic treatment calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines (TCVs) in endemic settings along with improvements in access to safe water, sanitation, and hygiene.

 

The findings from this 4-year study, the Severe Typhoid in Africa (SETA) program, offers new typhoid fever burden estimates from six countries: Burkina Faso, Democratic Republic of the Congo (DRC), Ethiopia, Ghana, Madagascar, and Nigeria, with four countries recording more than 100 cases for every 100,000 person-years of observation, which is considered a high burden. The highest incidence of typhoid was found in DRC with 315 cases per 100,000 people while children between 2-14 years of age were shown to be at highest risk across all 25 study sites.

 

There are an estimated 12.5 to 16.3 million cases of typhoid every year with 140,000 deaths. However, with generic symptoms such as fever, fatigue, and abdominal pain, and the need for blood culture sampling to make a definitive diagnosis, it is difficult for governments to capture the true burden of typhoid in their countries.

 

“Our goal through SETA was to address these gaps in typhoid disease burden data,” said lead author Dr. Florian Marks, Deputy Director General of the International Vaccine Institute (IVI). “Our estimates indicate that introduction of TCV in endemic settings would go to lengths in protecting communities, especially school-aged children, against this potentially deadly—but preventable—disease.”

 

In addition to disease incidence, this study also showed that the emergence of antimicrobial resistance (AMR) in Salmonella Typhi, the bacteria that causes typhoid fever, has led to more reliance beyond the traditional first line of antibiotic treatment. If left untreated, severe cases of the disease can lead to intestinal perforation and even death. This suggests that prevention through vaccination may play a critical role in not only protecting against typhoid fever but reducing the spread of drug-resistant strains of the bacteria.

 

There are two TCVs prequalified by the World Health Organization (WHO) and available through Gavi, the Vaccine Alliance. In February 2024, IVI and SK bioscience announced that a third TCV, SKYTyphoid™, also achieved WHO PQ, paving the way for public procurement and increasing the global supply.

 

Alongside the SETA disease burden study, IVI has been working with colleagues in three African countries to show the real-world impact of TCV vaccination. These studies include a cluster-randomized trial in Agogo, Ghana and two effectiveness studies following mass vaccination in Kisantu, DRC and Imerintsiatosika, Madagascar.

 

Dr. Birkneh Tilahun Tadesse, Associate Director General at IVI and Head of the Real-World Evidence Department, explains, “Through these vaccine effectiveness studies, we aim to show the full public health value of TCV in settings that are directly impacted by a high burden of typhoid fever.” He adds, “Our final objective of course is to eliminate typhoid or to at least reduce the burden to low incidence levels, and that’s what we are attempting in Fiji with an island-wide vaccination campaign.”

 

As more countries in typhoid endemic countries, namely in sub-Saharan Africa and South Asia, consider TCV in national immunization programs, these data will help inform evidence-based policy decisions around typhoid prevention and control.

 

###

 

About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.

IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO) and developed a new-generation typhoid conjugate vaccine that is recently pre-qualified by WHO.

IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden, a Country Office in Austria, and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, and Thailand provide state funding. For more information, please visit https://www.ivi.int.

 

CONTACT

Aerie Em, Global Communications & Advocacy Manager
+82 2 881 1386 | aerie.em@ivi.int


Read More

Continue Reading

International

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever… And Debt Explodes

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever… And Debt Explodes

Earlier today, CNBC’s…

Published

on

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever... And Debt Explodes

Earlier today, CNBC's Brian Sullivan took a horse dose of Red Pills when, about six months after our readers, he learned that the US is issuing $1 trillion in debt every 100 days, which prompted him to rage tweet, (or rageX, not sure what the proper term is here) the following:

We’ve added 60% to national debt since 2018. Germany - a country with major economic woes - added ‘just’ 32%.   

Maybe it will never matter.   Maybe MMT is real.   Maybe we just cancel or inflate it out. Maybe career real estate borrowers or career politicians aren’t the answer.

I have no idea.  Only time will tell.   But it’s going to be fascinating to watch it play out.

He is right: it will be fascinating, and the latest budget deficit data simply confirmed that the day of reckoning will come very soon, certainly sooner than the two years that One River's Eric Peters predicted this weekend for the coming "US debt sustainability crisis."

According to the US Treasury, in February, the US collected $271 billion in various tax receipts, and spent $567 billion, more than double what it collected.

The two charts below show the divergence in US tax receipts which have flatlined (on a trailing 6M basis) since the covid pandemic in 2020 (with occasional stimmy-driven surges)...

... and spending which is about 50% higher compared to where it was in 2020.

The end result is that in February, the budget deficit rose to $296.3 billion, up 12.9% from a year prior, and the second highest February deficit on record.

And the punchline: on a cumulative basis, the budget deficit in fiscal 2024 which began on October 1, 2023 is now $828 billion, the second largest cumulative deficit through February on record, surpassed only by the peak covid year of 2021.

But wait there's more: because in a world where the US is spending more than twice what it is collecting, the endgame is clear: debt collapse, and while it won't be tomorrow, or the week after, it is coming... and it's also why the US is now selling $1 trillion in debt every 100 days just to keep operating (and absorbing all those millions of illegal immigrants who will keep voting democrat to preserve the socialist system of the US, so beloved by the Soros clan).

And it gets even worse, because we are now in the ponzi finance stage of the Minsky cycle, with total interest on the debt annualizing well above $1 trillion, and rising every day

... having already surpassed total US defense spending and soon to surpass total health spending and, finally all social security spending, the largest spending category of all, which means that US debt will now rise exponentially higher until the inevitable moment when the US dollar loses its reserve status and it all comes crashing down.

We conclude with another observation by CNBC's Brian Sullivan, who quotes an email by a DC strategist...

.. which lays out the proposed Biden budget as follows:

The budget deficit will growth another $16 TRILLION over next 10 years. Thats *with* the proposed massive tax hikes.

Without them the deficit will grow $19 trillion.

That's why you will hear the "deficit is being reduced by $3 trillion" over the decade.

No family budget or business could exist with this kind of math.

Of course, in the long run, neither can the US... and since neither party will ever cut the spending which everyone by now is so addicted to, the best anyone can do is start planning for the endgame.

Tyler Durden Tue, 03/12/2024 - 18:40

Read More

Continue Reading

Trending